Interferon alpha 2 (alpha 2b), Recombinant, Human (Interferon alpha-2, IFN-alpha-2, IFNa2, IFNa2b, Interferon alpha-A, IFN-alphaA, IFNA, LeIF A, MGC125764, MGC125765)

Recombinant protein corresponding to 165aa of human Interferon-alpha 2b expressed in E.coli is a single, non-glycosylated, polypeptide chain.\n\nBiological Activity:\nThe specific activity as determined in a viral resistance assay using bovine kidney MDBK cells was found to be 2.6x10e8 IU/mg.\n\nDimers and Aggregates:\n(same/less than)1% (SDS-PAGE)\n\nProtein Content:\nProtein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm using the absorbency value of 0.924 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a calibrated solution of Recombinant corresponding to Interferon-alpha 2b as a Reference Standard.\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

I7661-75C

Size

100ug

Form

Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to (same/more than)0.1mg/ml.

Purity

~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: (same/less than)0.1ng/ug (IEU/ug)

References

1. Differential effects of interferon alpha-2b and beta on the signaling pathways in human liver cancer cells. J Gastroenterol 2005 Jul;40(7):722-32. 2. Treatment of early pterygium recurrence with topical administration of interferon alpha-2b. Can J Ophthalmol 2005 Apr;40(2):185-7. 3. p53 protein expression in chronic hepatitis C; effect of interferon alpha 2b therapy. Hepatogastroenterology 2005 Jul-Aug;52(64):1176-9. 4. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat 2005 Jul;12(4):380-5. 5. Safety and efficacy of an indigenous recombinant interferon-alpha-2b in patients with chronic myelogenous leukaemia: results of a multicentre trial from India. Natl Med J India 2005 Mar-Apr;18(2):66-70. 6. Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C. Dig Dis Sci 2005 May;50(5):970-5.